This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Codexis (CDXS) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Codexis (CDXS) delivered earnings and revenue surprises of 17.39% and 4.30%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
How Much Upside is Left in Codexis (CDXS)? Wall Street Analysts Think 219%
by Zacks Equity Research
The consensus price target hints at a 219.4% upside potential for Codexis (CDXS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Codexis (CDXS) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Codexis (CDXS) delivered earnings and revenue surprises of 16.67% and 9.74%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Codexis (CDXS) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Codexis (CDXS) delivered earnings and revenue surprises of 71.43% and 1.26%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Horizon Therapeutics (HZNP) Q2 Earnings and Revenues Lag Estimates
by Zacks Equity Research
Horizon Therapeutics (HZNP) delivered earnings and revenue surprises of -20.74% and 6.65%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Acadia Pharmaceuticals (ACAD) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Acadia (ACAD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate Codexis (CDXS) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Codexis (CDXS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Codexis (CDXS) Surges 9.7%: Is This an Indication of Further Gains?
by Zacks Equity Research
Codexis (CDXS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Codexis (CDXS) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Codexis (CDXS) delivered earnings and revenue surprises of 27.78% and 21.46%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Codexis (CDXS) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Codexis (CDXS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
After Plunging 39.6% in 4 Weeks, Here's Why the Trend Might Reverse for Codexis (CDXS)
by Zacks Equity Research
Codexis (CDXS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Codexis (CDXS) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Codexis (CDXS) delivered earnings and revenue surprises of 11.11% and 1.73%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Codexis (CDXS) Q4 Earnings Expected to Decline
by Zacks Equity Research
Codexis (CDXS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Codexis (CDXS) Surges 6.2%: Is This an Indication of Further Gains?
by Zacks Equity Research
Codexis (CDXS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
BridgeBio (BBIO) Begins Dosing with Gene Therapy in CAH Study
by Zacks Equity Research
BridgeBio (BBIO) doses the first patient in a phase I/II study evaluating its investigational gene therapy candidate, BBP-631, for treating classic congenital adrenal hyperplasia.
What Makes Codexis (CDXS) a New Strong Buy Stock
by Zacks Equity Research
Codexis (CDXS) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
3 Synthetic Biology Stocks in Focus With Strong Potential
by Indrajit Bandyopadhyay
Here we discuss three stocks - CDXS, PGEN, VERV - engaged in the field of scientific biology that investors may keep a tab of as these have the potential to generate wealth for them going forward.
Codexis (CDXS) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Codexis (CDXS) delivered earnings and revenue surprises of 133.33% and 27.85%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Will Codexis (CDXS) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Codexis (CDXS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's What Could Help Codexis (CDXS) Maintain Its Recent Price Strength
by Zacks Equity Research
If you are looking for stocks that are well positioned to maintain their recent uptrend, Codexis (CDXS) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Codexis (CDXS) Surges 12.4%: Is This an Indication of Further Gains?
by Zacks Equity Research
Codexis (CDXS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
After Golden Cross, Codexis (CDXS)'s Technical Outlook is Bright
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
Codexis (CDXS) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Codexis (CDXS) delivered earnings and revenue surprises of 58.82% and 41.06%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Emergent (EBS) Misses on Q2 Earnings, to Restart Bayview Unit
by Zacks Equity Research
Emergent's (EBS) second-quarter 2021 earnings miss estimates. Revenues also fail to meet expectations. Stock down.
Earnings Preview: Codexis (CDXS) Q2 Earnings Expected to Decline
by Zacks Equity Research
Codexis (CDXS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.